par Lambertini, Matteo ;Campbell, Christine;Bines, Jose;Korde, Larissa A;Izquierdo, Miguel;Fumagalli, Debora ;Del Mastro, Lucia;Ignatiadis, Michail ;Pritchard, Kathleen;Wolff, Antonio C;Jackisch, Christian;Lang, Istvan;Untch, Michael;Smith, Ian;Boyle, Frances;Xu, Binghe;Barrios, Carlos H;Baselga, José;Moreno-Aspitia, Alvaro;Piccart-Gebhart, Martine ;Gelber, Richard D;de Azambuja, Evandro
Référence Journal of the National Cancer Institute
Publication Publié, 2018-06
Référence Journal of the National Cancer Institute
Publication Publié, 2018-06
Article révisé par les pairs
Résumé : | In premenopausal patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, the gonadotoxicity of trastuzumab and lapatinib remains largely uncertain, and the prognostic effect of treatment-related amenorrhea (TRA) is unknown. |